e-learning
resources
Virtual 2021
08.09.2021
Genetics and translational aspects of idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Released mediators in ex vivo 3D-model of lung fibrosis correspond to elevated serum biomarkers in IPF
D. Kalafatis (Stockholm, Sweden), A. Löfdahl (Lund, Sweden), P. Näsman (Stockholm, Sweden), L. Elowsson Rendin (Lund, Sweden), G. Westergren-Thorsson (Lund, Sweden), M. Sköld (Stockholm, Sweden)
Source:
Virtual Congress 2021 – Genetics and translational aspects of idiopathic pulmonary fibrosis
Session:
Genetics and translational aspects of idiopathic pulmonary fibrosis
Session type:
Oral Presentation
Number:
4333
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Kalafatis (Stockholm, Sweden), A. Löfdahl (Lund, Sweden), P. Näsman (Stockholm, Sweden), L. Elowsson Rendin (Lund, Sweden), G. Westergren-Thorsson (Lund, Sweden), M. Sköld (Stockholm, Sweden). Released mediators in ex vivo 3D-model of lung fibrosis correspond to elevated serum biomarkers in IPF. 4333
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
PP231 – Released mediators in ex vivo 3D-model of lung fibrosis correspond to elevated serum biomarkers in IPF
Source: ERS Lung Science Conference 2021
Year: 2021
Clinically validated markers of the extracellular matrix remodelling are altered by potential anti-fibrotic compounds in a human lung fibrosis ex vivo model
Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Year: 2018
Extracellular matrix biomarkers predict change in lung function in idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Biomarkers and mechanistic aspects of idiopathic pulmonary fibrosis
Year: 2020
Different concentrations of CCL18 in serum and BALF of ILDs: A marker of pulmonary inflammation?
Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease
Year: 2010
PP102 – A serum biomarker reflecting human neutrophil elastase degraded calprotectin is elevated in COPD and IPF
Source: ERS Lung Science Conference 2021
Year: 2021
Elevation of serum tumor markers in patients with interstitial lung disease
Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease
Year: 2011
Extracorporal photosensitation in bleomycin-induced lung injury decreases IL-10 protein levels in BAL but not the level of inflammation
Source: Eur Respir J 2005; 26: Suppl. 49, 82s
Year: 2005
Plasma markers of oxidative protein damage do not correlate with lung function or COPD in smokers
Source: Eur Respir J 2006; 28: Suppl. 50, 144s
Year: 2006
Increased CCL18 production in interstitial lung diseases is associated with fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 38s
Year: 2004
Identifying serum molecular biomarkers that distinguish emphysema and early fibrotic interstitial lung disease.
Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia
Year: 2021
Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Plasma levels of circulating cell-free DNA are increased in idiopathic pulmonary fibrosis but do not correlate with disease severity
Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia
Year: 2019
Human β-defensin 2 and interleukin-8 as potential serum markers of pulmonary emphysema
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Profiling of COPD and IPF cytokine responses in human lung
Source: Virtual Congress 2021 – New insights into the airway immunology of lung disease
Year: 2021
Serum endostatin is a novel marker for COPD associated to lung function decline and exacerbation
Source: International Congress 2019 – Evaluation of basic science in airway diseases
Year: 2019
Eosinophil cationic protein stimulates TGF-β
1
release by human lung fibroblasts
Source: Annual Congress 2005 - Inflammation and remodelling in allergy and asthma
Year: 2005
Serum periostin is not a good biomarker to identify Th2-driven inflammation in COPD
Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD
Year: 2018
Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis
ex vivo
Source: Eur Respir J, 50 (2) 1602367; 10.1183/13993003.02367-2016
Year: 2017
Association of elevated CRP and IL-6 with rapid decline in lung function and exacerbation in tuberculosis destroyed lung
Source: International Congress 2017 – Classifying COPD with multidimensional scores and biomarkers
Year: 2017
BALF cells expression phenotypes and cytokine levels in BALF supernatant in fibrosing interstitial lung diseases
Source: Annual Congress 2012 - Diffuse parenchymal lung disease II
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept